Drug Trial Radar · NCT03455842
The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Nov 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Feb 1, 2018
Primary completion
Dec 31, 2018
Study completion Oct 22, 2019
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is Phase II randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety, pharmacokinetics and pharmacodynamics of 2 dosing regimens (qw and q2w, s/c) of monoclonal antibody to IL6R (BCD-089) in patients with active rheumatoid arthritis and inadequate response to methotrexate.
Conditions
- Seropositive RA
Interventions
BCD-089, 162 mg, s/c, qwBiological
Subcutaneous injections of anti-IL6R every week
BCD-089, 162 mg, s/c, q2wBiological
Subcutaneous injections of anti-IL6R every other week
placeboDrug
Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR20Time frame: week 12
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
1st City Clinical Hospital
Minsk, Belarus
Chelyabinsk Regional Clinical hospital
Chelyabinsk, Russia
Kazan State Medical University
Kazan', Russia
North-Western State Medical University n.a. I.I.Mechnikov
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.